deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 7-arm NCT04403763

Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Presbyopia

A First-in-Human, Phase 1/2, Dose-ascending, Multicenter, Masked, Randomized, Vehicle-controlled Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AGN-241622 in Healthy Participants and Participants With Presbyopia (Stage 1 and Stage 2) and Efficacy in Participants With Presbyopia (Stage 2)

Sponsor: AbbVie

Conditions Presbyopia
Interventions AGN-241622 Vehicle
Updated 14 times since 2020 Last updated: Jan 16, 2024 Started: Jul 27, 2020 Primary completion: Dec 5, 2022 Completion: Dec 5, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Strategic considerations

Other terminated trials from AbbVie

See all terminations from AbbVie

This PHASE1/PHASE2 trial investigates Presbyopia and is currently terminated or withdrawn. AbbVie leads this study, which shows 14 recorded versions since 2020 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jun 2020 – ~Sep 2020 · 3 months · monthly snapshot~Sep 2020 – ~Dec 2020 · 3 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Sep 2021 · 5 months · monthly snapshot~Sep 2021 – ~Nov 2021 · 2 months · monthly snapshot~Nov 2021 – ~Jan 2022 · 2 months · monthly snapshot~Jan 2022 – ~May 2022 · 4 months · monthly snapshot~May 2022 – ~Dec 2022 · 7 months · monthly snapshot~Dec 2022 – ~Jul 2023 · 7 months · monthly snapshot~Jul 2023 – ~Mar 2024 · 8 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Mar 2024 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

  4. Jul 2023 — Mar 2024 [monthly]

    Terminated PHASE1_PHASE2

    Status: Recruiting → Terminated

  5. Dec 2022 — Jul 2023 [monthly]

    Recruiting PHASE1_PHASE2

▶ Show 9 earlier versions

  1. May 2022 — Dec 2022 [monthly]

    Recruiting PHASE1_PHASE2

  2. Jan 2022 — May 2022 [monthly]

    Recruiting PHASE1_PHASE2

  3. Nov 2021 — Jan 2022 [monthly]

    Recruiting PHASE1_PHASE2

  4. Sep 2021 — Nov 2021 [monthly]

    Recruiting PHASE1_PHASE2

  5. Apr 2021 — Sep 2021 [monthly]

    Recruiting PHASE1_PHASE2

  6. Jan 2021 — Apr 2021 [monthly]

    Recruiting PHASE1_PHASE2

  7. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  8. Sep 2020 — Dec 2020 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  9. Jun 2020 — Sep 2020 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AbbVie
Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations